These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 21740293)

  • 1. Development of c-MET pathway inhibitors.
    Liu X; Newton RC; Scherle PA
    Expert Opin Investig Drugs; 2011 Sep; 20(9):1225-41. PubMed ID: 21740293
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Developing c-MET pathway inhibitors for cancer therapy: progress and challenges.
    Liu X; Newton RC; Scherle PA
    Trends Mol Med; 2010 Jan; 16(1):37-45. PubMed ID: 20031486
    [TBL] [Abstract][Full Text] [Related]  

  • 3. c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention.
    Christensen JG; Burrows J; Salgia R
    Cancer Lett; 2005 Jul; 225(1):1-26. PubMed ID: 15922853
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting angiogenesis in renal cell carcinoma.
    Posadas EM; Limvorasak S; Sharma S; Figlin RA
    Expert Opin Pharmacother; 2013 Nov; 14(16):2221-36. PubMed ID: 23984807
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel therapeutic inhibitors of the c-Met signaling pathway in cancer.
    Eder JP; Vande Woude GF; Boerner SA; LoRusso PM
    Clin Cancer Res; 2009 Apr; 15(7):2207-14. PubMed ID: 19318488
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting the MET pathway for potential treatment of NSCLC.
    Li A; Gao HF; Wu YL
    Expert Opin Ther Targets; 2015 May; 19(5):663-74. PubMed ID: 25532429
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Developing biomarkers to predict benefit from HGF/MET pathway inhibitors.
    Koeppen H; Rost S; Yauch RL
    J Pathol; 2014 Jan; 232(2):210-8. PubMed ID: 24105670
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [A simple view on lung cancer biology: the MET pathway].
    Ruppert AM; Beau-Faller M; Belmont L; Lavolé A; Gounant V; Cadranel J; Wislez M
    Rev Mal Respir; 2011 Dec; 28(10):1241-9. PubMed ID: 22152933
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Small molecule c-Met kinase inhibitors: a review of recent patents.
    Porter J
    Expert Opin Ther Pat; 2010 Feb; 20(2):159-77. PubMed ID: 20100000
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Progress in cancer therapy targeting c-Met signaling pathway.
    Jung KH; Park BH; Hong SS
    Arch Pharm Res; 2012 Mar; 35(4):595-604. PubMed ID: 22553051
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Osthole suppresses hepatocyte growth factor (HGF)-induced epithelial-mesenchymal transition via repression of the c-Met/Akt/mTOR pathway in human breast cancer cells.
    Hung CM; Kuo DH; Chou CH; Su YC; Ho CT; Way TD
    J Agric Food Chem; 2011 Sep; 59(17):9683-90. PubMed ID: 21806057
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MET signaling: novel targeted inhibition and its clinical development in lung cancer.
    Feng Y; Thiagarajan PS; Ma PC
    J Thorac Oncol; 2012 Feb; 7(2):459-67. PubMed ID: 22237263
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatocyte growth factor and Met in tumor biology and therapeutic approach with NK4.
    Matsumoto K; Nakamura T; Sakai K; Nakamura T
    Proteomics; 2008 Aug; 8(16):3360-70. PubMed ID: 18646008
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Single-agent and combination therapeutic strategies to inhibit hepatocyte growth factor/MET signaling in cancer.
    Toschi L; Jänne PA
    Clin Cancer Res; 2008 Oct; 14(19):5941-6. PubMed ID: 18829470
    [TBL] [Abstract][Full Text] [Related]  

  • 15. KRC-408, a novel c-Met inhibitor, suppresses cell proliferation and angiogenesis of gastric cancer.
    Hong SW; Jung KH; Park BH; Zheng HM; Lee HS; Choi MJ; Yun JI; Kang NS; Lee J; Hong SS
    Cancer Lett; 2013 May; 332(1):74-82. PubMed ID: 23348694
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The emerging role of MET/HGF inhibitors in oncology.
    Scagliotti GV; Novello S; von Pawel J
    Cancer Treat Rev; 2013 Nov; 39(7):793-801. PubMed ID: 23453860
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drug development of MET inhibitors: targeting oncogene addiction and expedience.
    Comoglio PM; Giordano S; Trusolino L
    Nat Rev Drug Discov; 2008 Jun; 7(6):504-16. PubMed ID: 18511928
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dual inhibition of Met kinase and angiogenesis to overcome HGF-induced EGFR-TKI resistance in EGFR mutant lung cancer.
    Takeuchi S; Wang W; Li Q; Yamada T; Kita K; Donev IS; Nakamura T; Matsumoto K; Shimizu E; Nishioka Y; Sone S; Nakagawa T; Uenaka T; Yano S
    Am J Pathol; 2012 Sep; 181(3):1034-43. PubMed ID: 22789825
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Small molecule c-MET inhibitor PHA665752: effect on cell growth and motility in papillary thyroid carcinoma.
    Chattopadhyay C; El-Naggar AK; Williams MD; Clayman GL
    Head Neck; 2008 Aug; 30(8):991-1000. PubMed ID: 18327775
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ARQ-197, an oral small-molecule inhibitor of c-Met for the treatment of solid tumors.
    Bagai R; Fan W; Ma PC
    IDrugs; 2010 Jun; 13(6):404-14. PubMed ID: 20506063
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.